8-K: Aardvark Expands PWS Trial Eligibility to Younger Children

Aardvark Therapeutics received IRB approval to lower the minimum age for its Phase 3 HERO trial of ARD-101 for Prader-Willi Syndrome from 10 to 7 years old.

Summary

• Aardvark Therapeutics, Inc. announced Institutional Review Board (IRB) approval in the U.S. for an amended protocol to its Phase 3 HERO pivotal clinical trial.
• The trial evaluates ARD-101 for treating hyperphagia in individuals with Prader-Willi Syndrome (PWS).
• The amended protocol lowers the minimum age of eligibility for trial participation from 10 to 7 years old.
• This expansion aims to reduce barriers to participation and broaden access for those affected by PWS, potentially better capturing ARD-101's impact.
• Enrollment in the HERO trial is progressing steadily and remains on track to report topline data in the third quarter of 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as expanding trial eligibility can accelerate enrollment and broaden the potential impact of ARD-101, though it's a procedural update rather than clinical data.

Positives

• IRB approval for an amended protocol in the U.S. for the Phase 3 HERO trial.
• Lowering the minimum age of eligibility from 10 to 7 years old expands the patient population.
• This expansion allows for broader access and potentially better capture of ARD-101's impact in younger PWS patients.
• Enrollment in the HERO trial is progressing steadily and remains on track.
• Topline data is expected in the third quarter of 2026.
• ARD-101 has Orphan Drug Designation and Rare Pediatric Disease Designation for PWS from the FDA.

Risks

• Uncertainties related to potential delays in the commencement, enrollment, and completion of clinical trials.
• Risk that capital resources may be used sooner than expected and be insufficient to achieve anticipated milestones.
• Risks related to dependence on third parties for manufacturing, shipping, and production of drug product.
• Risk of unfavorable clinical trial results.
• Risk that results from earlier clinical trials and preclinical studies may not necessarily be predictive of future results.
• Other risks and uncertainties described in Aardvark's Quarterly Report on Form 10-Q for the quarter ended September 30, 2025.

Future Outlook

The company expects to report topline data from the Phase 3 HERO trial in the third quarter of 2026. They believe these data will further inform the understanding of ARD-101's potential as a differentiated therapeutic approach for hyperphagia associated with PWS. The protocol expansion is intended to better capture the potential impact of ARD-101 in the PWS population by including younger children.

Management Comments

• "We are very pleased to report this important protocol expansion, which allows us to broaden the patient population for our Phase 3 HERO trial to include children as young as 7 years of age in the U.S." Tien Lee, M.D., Founder and CEO.
• "Hyperphagia may begin early in life for some individuals with PWS, and it presents a persistent burden for patients and caregivers. Expanding eligibility reflects our commitment to addressing the urgent need in the PWS community for a differentiated therapy and we aim to ensure broad and equitable access." Tien Lee, M.D., Founder and CEO.
• "Enrollment in HERO is progressing steadily and remains on track to report topline data in the third quarter of 2026." Tien Lee, M.D., Founder and CEO.
• "We believe these data will further inform our understanding of ARD-101s potential role as a differentiated therapeutic approach for the treatment of hyperphagia associated with PWS." Tien Lee, M.D., Founder and CEO.

Industry Context

StockSavvy.ai notes that expanding eligibility criteria for rare disease trials is a common strategy to accelerate enrollment and ensure a more representative patient population, especially when the disease manifests early in life. This move aligns with broader industry efforts to address unmet medical needs in pediatric populations and could enhance the commercial potential of ARD-101 by demonstrating efficacy across a wider age range.

Comparison to Industry Standards

• Expanding trial eligibility to younger age groups is a standard practice in rare pediatric disease development, aiming to capture the full disease spectrum and potential benefits of early intervention.
• Companies like Sarepta Therapeutics (e.g., for Duchenne muscular dystrophy) and PTC Therapeutics (e.g., for AADC deficiency) have similarly adjusted trial protocols to include younger patients to optimize data collection and accelerate regulatory pathways for pediatric indications.
• The use of validated questionnaires like HQ-CT and CaGI-S as primary and secondary endpoints is consistent with industry standards for assessing symptom severity and caregiver burden in rare neurological and metabolic disorders.

Stakeholder Impact

• Shareholders: Potential for increased value if the expanded trial leads to faster enrollment, successful results, and broader market access for ARD-101.
• Patients (PWS individuals aged 7-9): Gained access to a potential new therapy through the clinical trial, addressing an unmet medical need.
• Caregivers: Potential for relief from the burden of hyperphagia if ARD-101 proves effective, and broader access to the trial.
• Regulatory Authorities (FDA): Continued engagement through protocol amendments and ongoing trial oversight.

Next Steps

• Continue enrollment in the Phase 3 HERO trial across the U.S., Australia, Canada, the United Kingdom, and South Korea.
• Report topline data from the Phase 3 HERO trial in the third quarter of 2026.
• Participants completing the 12-week clinical trial will have the option to participate in an Open Label Extension trial.
• Aardvark is also developing ARD-201, a planned fixed-dose combination, through two separate Phase 2 trials.

Key Dates

Recommendation

The announcement is a positive procedural step that expands the potential patient pool for the ongoing Phase 3 trial, which is good for trial progress and future market potential. However, it does not provide new clinical data or financial results. The stock is likely to react positively to the increased probability of successful trial completion and broader market, but it's not a definitive catalyst for a "buy" recommendation without actual clinical outcomes. The risks associated with clinical trials remain. Therefore, a "hold" is appropriate for investors awaiting topline data in Q3 2026.

Keywords

Prader-Willi Syndrome, PWS, ARD-101, hyperphagia, Phase 3 clinical trial, HERO trial, biopharmaceutical, rare disease, clinical-stage, FDA, IRB, orphan drug, rare pediatric disease